Supernus Pharmaceuticals (SUPN) Finished Goods (2013 - 2026)

Supernus Pharmaceuticals (SUPN) has 14 years of Finished Goods data on file, last reported at $19.5 million in Q1 2026.

• Finished Goods for Q1 2026 came in at $19.5 million, down 11.46% year-over-year; the trailing twelve-month figure through Mar 2026 was $19.5 million (down 11.46% YoY), and the FY2025 annual result was $21.1 million, up 28.44% from the prior year.
• Finished Goods slipped to $19.5 million in Q1 2026 per SUPN's latest filing, from $21.1 million in the prior quarter.
• Over five years, Finished Goods peaked at $46.7 million in Q3 2022 and troughed at $16.4 million in Q4 2024.
• A 5-year average of $29.1 million and a median of $29.9 million in 2023 frame the typical range for Finished Goods.
• The sharpest annual moves came in 2022 and 2024: Finished Goods surged 272.49% in 2022, then sank 45.05% in 2024.
• A 5-year view of Finished Goods shows it stood at $35.0 million in 2022, then decreased by 14.54% to $29.9 million in 2023, then slumped by 45.05% to $16.4 million in 2024, then increased by 28.44% to $21.1 million in 2025, then decreased by 7.48% to $19.5 million in 2026.
• Business Quant data shows SUPN's Finished Goods at $19.5 million in Q1 2026, $21.1 million in Q4 2025, and $16.7 million in Q3 2025.